Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O14593
UPID:
RFXK_HUMAN
Alternative names:
Ankyrin repeat family A protein 1; Regulatory factor X subunit B; Regulatory factor X-associated ankyrin-containing protein
Alternative UPACC:
O14593; O95839; Q24JQ1; Q6FGA8
Background:
DNA-binding protein RFXANK, also known as Regulatory factor X subunit B, plays a pivotal role in immune response. It activates transcription from class II MHC promoters, essential for a functional adaptive immune system. RFXANK's interaction with MHC class II transactivator/CIITA is crucial for this process, highlighting its significance in gene regulation and immune defense mechanisms.
Therapeutic significance:
RFXANK's mutation leads to Bare lymphocyte syndrome 2, a severe immunodeficiency disorder. This condition underscores the protein's critical role in immune system functionality. Understanding RFXANK's mechanisms offers a pathway to novel treatments for immune-related diseases, emphasizing the importance of targeted therapeutic strategies.